Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HRAS | P01112 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741620 | 0.85 | NPC1 (0.56) | NPC1RAB9AIDO1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL28129374 | 0.83 | NPC1 (0.55) | NPC1RAB9AIDO1NOS3NOS1 | |
| SCHEMBL1741631 | 0.83 | RAB9A (0.47) | NPC1RAB9AIDO1AGXTEPHX2 | |
| Acetic Acid SCHEMBL27764846 | 0.77 | NPC1 (0.57) | NPC1RAB9AEPHX2 | |
| SCHEMBL8011483 | 0.76 | NPC1 (0.51) | NPC1RAB9AIDO1EPHX2 | |
| SCHEMBL9395489 | 0.76 | KMT2A (0.46) | NPC1RAB9A | |
| SCHEMBL27966484 | 0.75 | L3MBTL1 (0.46) | TSHR | |
| SCHEMBL27836323 | 0.75 | NPC1 (0.46) | NPC1RAB9AIDO1EPHX2 | |
| SCHEMBL1520136 | 0.74 | GRIN2D (0.49) | IDO1TSHR | |
| SCHEMBL6459391 | 0.74 | NPC1 (0.62) | NPC1RAB9AIDO1AGXTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| WO-1996015671-A1 | HERBICIDES | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996015672-A1 | FUNGICIDAL COMPOSITION | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| US-5300503-A | Larvicides | FMC CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | NPC1 1592/4885RAB9A 2328/4885IDO1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.